Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharma to raise quarter of a billion dollars from US investors

It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.
GW Pharma to raise quarter of a billion dollars from US investors
American investors have been tapped for cash.

The UK’s GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH), a world leader in cannabis-based medicines, has outlined plans to raise US$252mln from US investors.

It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.

The stock is being offer at US$90, a modest discount to last night’s closing price of US$97.

The company said it will file next year for regulatory approval in the US for Epidiolex, used to treat severe epilepsy in children, after what were described as “stellar” late stage clinical trial results.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

viagra.jpg
May 31 2017
Written responses from America’s Food & Drug Administration and the Medicines & Healthcare products Regulatory Agency (MHRA) here in Britain support its timeline, which sees marketing approval for the product in the second-quarter of 2019.
genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
picture of drug research
Tue
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use